WO2003105990A2 - Filter material for toxins, bacteria, viruses, and other harmful physiological substances - Google Patents
Filter material for toxins, bacteria, viruses, and other harmful physiological substances Download PDFInfo
- Publication number
- WO2003105990A2 WO2003105990A2 PCT/EP2003/005957 EP0305957W WO03105990A2 WO 2003105990 A2 WO2003105990 A2 WO 2003105990A2 EP 0305957 W EP0305957 W EP 0305957W WO 03105990 A2 WO03105990 A2 WO 03105990A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- filter material
- material according
- aryl
- alkyl
- acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3204—Inorganic carriers, supports or substrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/20—Pathogenic agents
- A61M2202/203—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/20—Pathogenic agents
- A61M2202/206—Viruses
Definitions
- the invention relates to a filter material for toxins, bacteria, viruses and other physiological pollutants, which can be used in hemoperfusion to rid the blood of such pollutants.
- the filter material is based on compounds from the class of calixarenes and reosrcinarene.
- Hemoperfusion is one of the (most effective measures for extracorporeal elimination of toxins and pollutants.
- hemoperfusion In contrast to hemodialysis, hemoperfusion is able to eliminate lipophilic substances that are not suitable for dialysis from the blood. However, hemoperfusion is usually superior to substances capable of dialysis. An important side effect, which has not yet been eliminated, is the undesired adsorption of throinocytes, which can be in a range up to about 40%.
- a filter material which consists of a compound of the general formula I
- R H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with • 1 to 12 carbon atoms, amino acids, sugar or crown ether,
- Ri H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with 1 to 12 carbon atoms, sulfonamides, amino acids, sugars, crown ethers, cyclodextrins, purine bases or pyridine bases,
- R H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with 1 to 12 carbon atoms or amino acids
- Ri H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with 1 to 12 carbon atoms, sulfona ide, amino acids, sugar, crown ethers, cyclodextrins, purine bases or pyrimidine bases,
- R 2 * alkyl or aryl
- R 3 and 4 0, where R 3 and R are bridged together via methylene, ethylene or quinoxaline
- the designated aromatic systems can be any heteroatoms, e.g. B. 0, S, N, have.
- the peculiarity of the solution according to the invention is based on the fact that the macromolecules used from the group of the calixarenes and resorcinarenes are easily accessible synthetically and can be modified universally. So you can open them up. Optimize various requirements regarding the substance classes of the toxins to be eliminated. It is particularly interesting in view of the fact that a large number of substances have hitherto been insufficiently eliminated, for example B. Paraquat and Diquat.
- any matrices known from the prior art can be used as the carrier.
- the filter material it is also possible for the filter material to contain or consist of biomatrixes such as cotton or cellulose.
- Micelle formers or compounds from the group cyclodextrins are preferably contained as additives.
- cyclodextrins are significantly more polar and hydrophilic than calixarenes or resorcinarenes, which means that. certain applications a higher hydrophilicity of the filter material than can be realized.
- the calixarenes or resorcinarenes of the general formulas I and II must be modified depending on the pollutant to be eliminated.
- the modification takes place from the point of view of optimizing the interaction between the filter material and the relevant target molecule, ie. H. the pollutant.
- hydrophilic groups in the compounds are necessary to ensure water solubility.
- modification options of the filter material are to be mentioned here only by way of example in order to implement special applications. This includes, on the one hand, modifying the filter material with sugars that can interact with bacteria, making them accessible for hemoperfusion, so that they can be filtered out of physiological fluids. By modifying the filter material with amino acids, an interaction with viruses can also be made possible, so that these can also be separated using hemoperfusion.
- the filter material provides that the compound of the general formulas I and II are modified with antibodies. This enables the rapid elimination of antigens due to antigen-antibody interactions. With aggressive viruses in particular, there is the possibility of removing antigens from the organism until the immune system has stabilized.
- the filter material is based on the fact that the compounds of the general formulas I and II have a high temperature resistance, which can be exploited in such a way that recyclable filter materials can be provided.
- Appropriate thermal treatment thermally decomposes the pollutants eliminated from the blood, while the compounds of the general formulas I and II contained in the filter material remain stable. Such thermal treatments are preferably carried out above 300 ° C. Compared to the filter materials known from the prior art, the inventive materials thus have a significantly higher thermal stability.
- the filter material is preferably integrated into common filter devices. This includes, for example, cartridges, frits, disks or membranes.
- the filter material according to the invention is preferably used for the hemoperfusion of physiological liquids.
- Blood, plasma or urine are only examples of physiological fluids.
- the subject according to the invention is intended to be explained in more detail with reference to the following figure and the examples, without restricting it to the exemplary embodiments mentioned.
- 1 shows a schematic structural model of the tetrasulfonic acid calix [4] arene-paraquat complex.
- a paraquat molecule shows the incorporation of a paraquat molecule into a tetrasulfonic acid calix [4] arene system.
- the paraquat is bound to the filter material via different interactions. This includes a cation-OH interaction 1, a cation- ⁇ interaction 2, a CH- ⁇ interaction 3 and a ⁇ - ⁇ interaction 4.
- the complex formation constant is very large and can be in the range 10 5 are up to 10 ⁇ . This means that paraquat is stored irreversibly and can thus be permanently removed from the bloodstream, for example by hemoperfusion.
- the sulfuric acid is added all at once to the calix [4] arene in a 100 ml three-necked flask with gas inlet and outlet devices.
- the apparatus is flushed with argon and the reaction mixture is stirred at 80 ° C. for about 4 hours.
- the course of the reaction is followed by taking a sample and checking the solubility in water. If the mixture is soluble in water without a residue, the reaction is stopped.
- the crude product is filtered off with a glass frit (4 A), dissolved in methanol (in order to remove remaining sulfuric acid) and precipitated with ethyl acetate.
- the white precipitate is dried in an oil pump vacuum-
- Paraquat is a very effective contact herbicide and as such has been widely used for many decades.
- the toxic effect on plants is based on the inhibition of photosynthesis by the formation of radical intermediates which prevent the NADP reduction. This hinders the transmission of energy. It is 'non-toxic to rapidly oxygen, reduced well waser- soluble compounds, whereby it is a good way to carry out the control of weeds in time selectively and relatively umweitschonend' in the field in the presence of light and.
- Paraquat has repeatedly resulted in numerous acute and chronic poisonings in humans when used in agriculture or when attempting suicide. Symptoms such as eye damage, kidney and liver damage, gastritis and lung diseases occur until death from suffocation. Therapeutic measures are limited because there is no specific antidote. Adsorption on activated carbon or carbon filters is weak, which is why stronger interactions with adsorbents are sought.
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Filter aterial für Toxine, Bakterien, Viren und andere physiologische Schadstoffe Filter aterial for toxins, bacteria, viruses and other physiological pollutants
Die Erfindung- betrifft ein Filtermaterial für Toxine, Bakterien, Viren und andere physiologische Schadstoffe, das bei der Hä operfusion zur Befreiung des Blutes von derartigen Schadstoffen eingesetzt werden kann. Das Filtermaterial basiert dabei auf Verbindungen aus der Klasse der Calixarene und Reosrcinarene .The invention relates to a filter material for toxins, bacteria, viruses and other physiological pollutants, which can be used in hemoperfusion to rid the blood of such pollutants. The filter material is based on compounds from the class of calixarenes and reosrcinarene.
Die Hämoperfusion gehört zu den (Wirkungsvollsten Massnah en zur extrakorpσralen Gift- und- Schadstoffelimination.Hemoperfusion is one of the (most effective measures for extracorporeal elimination of toxins and pollutants.
Aus dem Stand der Technik ist es bislang bekannt, das dem Patienten entnommene Blut durch Adsorberkartu- schen zu leiten, die Gift- oder Schadstoffe dabei an den Adsorbentien zu binden und damit dem Blut zu entziehen. Bislang wurden Materialien mit bekannt guten Adsorptionseigenschaften, wie z.B. beschichtete Ak- tivkohle oder Neutralharze, eingesetzt. Weitere Ad- sorber aterialien basieren auf funktionalisierten Polymermatrizes. In all diesen Fällen gibt es jedoch eine Vielzahl von Substanzen und Substanzklassen, welche schlecht bzw. gar nicht gebunden und damit abgetrennt werden können. Ein Beispiel hierfür sind Bakterien und Viren, für die bislang keinerlei Adsor- ber aterialien existieren.It is previously known from the prior art to pass the blood drawn from the patient through adsorber cartridges, to bind the toxins or pollutants to the adsorbents and thus to withdraw them from the blood. So far, materials with known good adsorption properties, such as coated ac- tiv carbon or neutral resins. Additional adsorbent materials are based on functionalized polymer matrices. In all of these cases, however, there are a large number of substances and classes of substances which can be poorly or not at all bound and thus separated. An example of this are bacteria and viruses, for which no adsorber materials exist so far.
Im Gegensatz zur Hämodialyse ist die Hämoperfus-iön imstande, auch lipophile, nicht dialysetauglicne Substanzen aus dem Blut zu eliminieren. Aber auch bei dialysefähige Substanzen ist die Hämoperfusion in der Regel überlegen. Eine wesentliche, und bislang nicht zu beseitigende Nebenwirkung ist die unerwünschte Ad- soprtion von Throinbozyten, die in einem Bereich bis etwa 40 % liegen kann.In contrast to hemodialysis, hemoperfusion is able to eliminate lipophilic substances that are not suitable for dialysis from the blood. However, hemoperfusion is usually superior to substances capable of dialysis. An important side effect, which has not yet been eliminated, is the undesired adsorption of throinocytes, which can be in a range up to about 40%.
Ausgehend hiervon war es Aufgabe der vorliegenden Er- findung, ein Filtermaterial für die Hämoperfusion bereitzustellen, dass nicht die aus dem Stand der Technik bekannten Nachteile aufweist, bezüglich der Filtereigenschaften eine hohe Effizienz zeigt und auf einfache Weise an spezielle Aufgabenstellungen im Be- reich der Hämoperfusion angepasst werden kanϊt,-- ,Proceeding from this, it was an object of the present invention to provide a filter material for hemoperfusion which does not have the disadvantages known from the prior art, which is highly efficient with regard to the filter properties and which can be easily adapted to special tasks in the field of hemoperfusion can be adjusted, -,
Diese Aufgabe wird durch das Filtermaterial mit den Merkmalen des Anspruchs 1 gelöst. Die weiteren abhängigen Ansprüche zeigen vorteilhafte Weiterbildungen auf. In Anspruch 9 wird die Verwendung des Filtermaterials beschrieben.This object is achieved by the filter material with the features of claim 1. The further dependent claims show advantageous developments. In claim 9, the use of the filter material is described.
Erfindungsgemäß wird ein Filtermaterial bereitgestellt, das aus einer Verbindung der allgemeinen For- el I According to the invention, a filter material is provided which consists of a compound of the general formula I
it R = H, Alkyl, Aryl, Alkyloxy, Aryloxy, A in, Amid, Carbonsäuren und Sulfonsäuren mit • 1 bis 12 C-Atomen, Aminosäuren, Zucker oder Kronenether,it R = H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with • 1 to 12 carbon atoms, amino acids, sugar or crown ether,
Ri =H, Alkyl, Aryl, Alkyloxy, Aryloxy, Ain, Amid, Carbonsäuren und Sulfonsäuren mit 1 bis 12 C-Atomen, Sulfon-amide, Aminosäuren, Zucker, Kronenether, Cyclodex- trine, Purinbasen oder Pyri idinb.asen,Ri = H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with 1 to 12 carbon atoms, sulfonamides, amino acids, sugars, crown ethers, cyclodextrins, purine bases or pyridine bases,
X = Methylen, S, 0, N oder P undX = methylene, S, 0, N or P and
m =** 4, 5, 6 oder 8m = ** 4, 5, 6 or 8
und/oder einer Verbindung der allgemeinen Formel IIand / or a compound of the general formula II
mit R = H, Alkyl, Aryl, Alkyloxy, Aryloxy, Amin, Amid, Carbonsäuren und Sulfonsäuren mit 1 bis 12 C-Atomen oder Aminosäuren, Ri =H, Alkyl, Aryl, Alkyloxy, Aryloxy, Amin, Amid, Carbonsäuren und Sulfonsäuren mit 1 bis 12 C-Atomen, Sulfona ide, Aminosäuren, Zucker, Kronenether, Cyclodex- trine, Purinbasen oder Pyrimidinbasen,with R = H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with 1 to 12 carbon atoms or amino acids, Ri = H, alkyl, aryl, alkyloxy, aryloxy, amine, amide, carboxylic acids and sulfonic acids with 1 to 12 carbon atoms, sulfona ide, amino acids, sugar, crown ethers, cyclodextrins, purine bases or pyrimidine bases,
R2 *=Alkyl oder Aryl,R 2 * = alkyl or aryl,
X = Methylen, S, 0, N oder P,X = methylene, S, 0, N or P,
r = 4, 5, 6 oder 8,r = 4, 5, 6 or 8,
undand
R3 =Hydroxyl und R4 = HR 3 = hydroxyl and R 4 = H
oderor
R3 und 4 = 0, wobei R3 und R über Methylen, Ethylen oder Chinoxalin miteinander verbrückt sindR 3 and 4 = 0, where R 3 and R are bridged together via methylene, ethylene or quinoxaline
sowie mindestens einem Trägerstoff und/oder Additiv. Dabei können die bezeichneten aromatischen Systeme beliebige Heteroatome, z. B. 0, S, N, aufweisen.and at least one carrier and / or additive. The designated aromatic systems can be any heteroatoms, e.g. B. 0, S, N, have.
Die Besonderheit der erfindungsgemäßen Lösung beruht darauf, daß die verwendeten Makromoleküle aus der Gruppe der Calixarene und Resorcinarene synthetisch leicht zugänglich und universell modifizierbar sind. Somit kann man sie auf. verschiedenste Anforderungen bezüglich der Substanzklassen der zu eliminierenden Giftstoffe optimieren. Es ist insbesondere im Hin- blick darauf interessant, daß eine Vielzahl von Substanzen bisher nur ungenügend eliminiert werden kann, z. B. Paraquat und Diquat.The peculiarity of the solution according to the invention is based on the fact that the macromolecules used from the group of the calixarenes and resorcinarenes are easily accessible synthetically and can be modified universally. So you can open them up. Optimize various requirements regarding the substance classes of the toxins to be eliminated. It is particularly interesting in view of the fact that a large number of substances have hitherto been insufficiently eliminated, for example B. Paraquat and Diquat.
Als Trägerstoff können beliebige aus dem Stand der Technik bekannte Matrizes verwendet werden. Bevorzugt werden hierbei handelsübliche Matrizes auf Polymerbasis oder anorganische Oxide oder Matrizes, z.B. Kieselgel, Aluminiumoxid, Wolframoxid oder Zeolithe, verwendet. Ebenso ist es aber auch möglich, daß das Filtermaterial Biomatrixes wie Baumwolle oder Zellulose enthält oder daraus besteht.Any matrices known from the prior art can be used as the carrier. Prefers commercially available matrices based on polymers or inorganic oxides or matrices, for example silica gel, aluminum oxide, tungsten oxide or zeolites, are used. However, it is also possible for the filter material to contain or consist of biomatrixes such as cotton or cellulose.
Als Additive sind bevorzugt Micellenbildner oder Verbindungen aus der Gruppe Cyclodextrine enthalten.Micelle formers or compounds from the group cyclodextrins are preferably contained as additives.
Cyclodextrine sind aufgrund der hohen Hydroxylfunk- tionalität deutlich polarer und hydrophiler als Ca- lixarene bzw. Resorcinarene, wodurch für. bestimmte Anwendungen eine höhere Hydrophilie des Filtermateri- als realisiert werden kann.Due to the high hydroxyl functionality, cyclodextrins are significantly more polar and hydrophilic than calixarenes or resorcinarenes, which means that. certain applications a higher hydrophilicity of the filter material than can be realized.
Die Calixarene bzw. Resorcinarene der allgemeinen Formeln I und II sind in Abhängigkeit von dem zu eliminierenden Schadstoff zu modifizieren. Die Modifi- zierung erfolgt dabei unter dem Gesichtspunkt der Optimierung der Wechselwirkung zwischen dem Filtermaterial und dem betreffenden Target-Molekül, d. h. dem Schadstoff. Gleichzeitig sind hydrophile Gruppen in den Verbindungen notwendig, um die Wasserlöslichkeit zu gewährleisten.The calixarenes or resorcinarenes of the general formulas I and II must be modified depending on the pollutant to be eliminated. The modification takes place from the point of view of optimizing the interaction between the filter material and the relevant target molecule, ie. H. the pollutant. At the same time, hydrophilic groups in the compounds are necessary to ensure water solubility.
Hier sollen nur beispielhaft verschiedene Modifizie- rungs öglichkeiten des Filtermaterials genannt werden, um spezielle Anwendungen zu realisieren. Hierzu zählt zum einen die Modifizierung des Filtermaterials mit Zuckern, die mit Bakterien wechselwirken können, wodurch diese für die Hämoperfusion zugänglich sind, so daß diese aus physiologischen Flüssigkeiten her- ausgefiltert werden können. Ebenso kann durch die Mo- difizierung des Filtermaterials mit Aminosäuren eine Wechselwirkung mit Viren ermöglicht werden, so daß auch diese mittels der Hämoperfusion abtrennbar sind.Various modification options of the filter material are to be mentioned here only by way of example in order to implement special applications. This includes, on the one hand, modifying the filter material with sugars that can interact with bacteria, making them accessible for hemoperfusion, so that they can be filtered out of physiological fluids. By modifying the filter material with amino acids, an interaction with viruses can also be made possible, so that these can also be separated using hemoperfusion.
Eine weitere vorteilhafte Weiterbildung des Filtermaterials sieht vor, daß die Verbindung der allgemeinen Formeln I und II mit Antikörpern modifiziert sind. Hierdurch wird die rasche Elimination von Antigenen auf Grund von Antigen-Antikörper-Wechselwirkungen ermöglicht. Insbesondere bei agressiven Viren besteht dadurch die Möglichkeit, Antigene aus dem Organismus zu entfernen bis sich das Imunsystem stabilisiert hat.Another advantageous development of the filter material provides that the compound of the general formulas I and II are modified with antibodies. This enables the rapid elimination of antigens due to antigen-antibody interactions. With aggressive viruses in particular, there is the possibility of removing antigens from the organism until the immune system has stabilized.
Ein weiterer besonderer Vorteil des Filtermaterials beruht darauf, daß die Verbindungen der allgemeinen Formeln I und II eine hohe Temperaturbeständigkeit aufweisen, was- sich in der Weise ausnutzen läßt, daß recyclingfähige Filtermaterialen bereitgestellt werden können. Durch eine entsprechende thermische Behandlung werden dabei die aus dem Blut eliminierten Schadstoffe thermisch zersetzt, während die im Filtermaterial enthaltenen Verbindungen der allgemeinen Formeln I und II stabil bleiben. Bevorzugt werden derartige thermische Behandlungen oberhalb von 300°C durchgeführt. Gegenüber den aus dem Stand der Technik bekannten Filtermaterialien weisen die erfindungsgemäßen damit eine deutlich höhere thermische Stabilität auf.Another particular advantage of the filter material is based on the fact that the compounds of the general formulas I and II have a high temperature resistance, which can be exploited in such a way that recyclable filter materials can be provided. Appropriate thermal treatment thermally decomposes the pollutants eliminated from the blood, while the compounds of the general formulas I and II contained in the filter material remain stable. Such thermal treatments are preferably carried out above 300 ° C. Compared to the filter materials known from the prior art, the inventive materials thus have a significantly higher thermal stability.
Vorzugsweise wird das Filtermaterial in gängige Fil- tervorrichtungen integriert. Hierzu zählen beispielsweise Kartuschen, Fritten, Disks oder Membranen.The filter material is preferably integrated into common filter devices. This includes, for example, cartridges, frits, disks or membranes.
Das erfindungsgemäße Filtermaterial findet bevorzugt für die Hämoperfusion von physiologischen Flüssigkei- ten Anwendung. Als physiologische Flüssigkeiten seien nur beispielsweise Blut, Plasma oder Urin genannt. Anhand der nachfolgenden Figur und der Beispiele soll der erfindungsgemäße Gegenstand näher erläutert werden, ohne diesen auf die genannten Ausführungsbei- spiele zu beschränken.The filter material according to the invention is preferably used for the hemoperfusion of physiological liquids. Blood, plasma or urine are only examples of physiological fluids. The subject according to the invention is intended to be explained in more detail with reference to the following figure and the examples, without restricting it to the exemplary embodiments mentioned.
Fig. 1 zeigt ein schematisches Strukturmodell des Tetrasulfonsäurecalix [4] aren-Paraquat-Komplexes .1 shows a schematic structural model of the tetrasulfonic acid calix [4] arene-paraquat complex.
In Fig. 1 ist der Einbau eines Paraquat-Moleküls in ein Tetrasulfonsäurecalix[4] aren-System dargestellt. Das Paraquat wird dabei über unterschiedliche Wechselwirkungen an das Filtermaterial gebunden. Hierzu zählt zum einen eine Kation-OH-Wechselwirkung 1, eine Kation-π-Wechselwirkung 2, eine CH-π-Wechselwirkung 3 und eine π-π-Wechselwirkung 4. Die Ko plexbildungs- kσnstante ist sehr groß und kann im Bereich 105 bis 10δ liegen. Das bedeutet, daß Paraquat irreversibel eingelagert wird und damit durch Hämoperfusion z.B. aus dem Blutkreislauf dauerhaft entfernt werden kann.1 shows the incorporation of a paraquat molecule into a tetrasulfonic acid calix [4] arene system. The paraquat is bound to the filter material via different interactions. This includes a cation-OH interaction 1, a cation-π interaction 2, a CH-π interaction 3 and a π-π interaction 4. The complex formation constant is very large and can be in the range 10 5 are up to 10 δ . This means that paraquat is stored irreversibly and can thus be permanently removed from the bloodstream, for example by hemoperfusion.
Beispiel 1example 1
Synthese von '5, 11 , 17 ,23-Tetrasulfonsäurecalix [4] arenSynthesis of ' 5, 11, 17, 23-tetrasulfonic acid calix [4] arenes
Die Darstellung erfolgt nach dem in Formel III dargestellten ReaktionsSchema:The representation follows the reaction scheme shown in Formula III:
Folgende Ausgangsverbindungen wurden eingesetzt: Calix[4] aren (7 mmo1' 3 g Schwefelsäure (98%) 30 ml Methanol, Ethylacetat. The following starting compounds were used: Calix [4] arene (7 mm 3 -3 g sulfuric acid (98%) 30 ml methanol, ethyl acetate.
In einem 100-ml-Dreihalskolben mit Gas-Ein- und -Aus- laßvσrrichtung wird die Schwefelsäure auf einmal zum Calix[4]aren zugegeben. Die Apparatur wird mit Argon gespült und das Reaktionsgemisch bei 80 °C etwa 4 Stunden gerührt. Der Reaktionsverlauf wird durch Probeentnahme und Löslichkeitsüberprüfung in Wasser verfolgt. Ist das Gemisch ohne Rückstand in Wasser löslich, wird die Reaktion abgebrochen. Das Rohprodukt wird mit einer Glasfritte (4 A) abgesaugt, in Methanol gelöst (um verbliebene Schwefelsäure zu entfernen) und mit Ethylacetat gefällt. Der weiße Niederschlag wird am ÖlpumpenVakuum getrocknet-The sulfuric acid is added all at once to the calix [4] arene in a 100 ml three-necked flask with gas inlet and outlet devices. The apparatus is flushed with argon and the reaction mixture is stirred at 80 ° C. for about 4 hours. The course of the reaction is followed by taking a sample and checking the solubility in water. If the mixture is soluble in water without a residue, the reaction is stopped. The crude product is filtered off with a glass frit (4 A), dissolved in methanol (in order to remove remaining sulfuric acid) and precipitated with ethyl acetate. The white precipitate is dried in an oil pump vacuum-
Die Ausbeute betrug 4,25 g (68 % d. Lit.) .The yield was 4.25 g (68% of lit.).
Folgende analytische Kenndaten konnten bestimmt werden:The following analytical characteristics could be determined:
IR (KBr, RT) :IR (KBr, RT):
3372, 3224, 3125 (V0H) ; 1473, 1461 (δCH2) 1171 (Vso2) .3372, 3224, 3125 (V 0H ); 1473, 1461 (δ CH2 ) 1171 (Vso 2 ).
αH-NMR (400 MHz, D20, δ = 4,65 ppm) : α H-NMR (400 MHz, D 2 0, δ = 4.65 ppm):
7,40 (s, 8H, Ar-H) ; 3,82 (br s, 8H, Ar-CH2-Ar)7.40 (s, 8H, Ar-H); 3.82 (br s, 8H, Ar-CH 2 -Ar)
13C-NMR ( 400 MHz , D20 , CH3OH, δ = 50 , 2 pp ) : 13 C-NMR (400 MHz, D 2 0, CH 3 OH, δ = 50, 2 pp):
153 , 29 (C-OH) ; 137 , 24 (C-SO3H) ; 129 , 83 (Ca --CH2- ) ; 128 , 03 (Car)' ; 32 , 05 (Car-CH2-Car) . MS (MALDI-TOF) : m/ e=7 67 , l [M+Na ] ' (berechnet für C28H24O16S4 : M=744 , 8 g/mol )153, 29 (C-OH); 137, 24 (C-SO3H); 129, 83 (C a --CH 2 -); 128.03 (C ar ) ' ; 32.05 (C ar -CH 2 -C ar ). MS (MALDI-TOF): m / e = 7 67, l [M + Na] ' (calculated for C 2 8H 24 O 16 S 4 : M = 744, 8 g / mol)
Beispiel 2Example 2
Hämoperfusion zur Entgiftung von ParaquatHemoperfusion to detoxify paraquat
Bei den Untersuchungen der Wechselwirkungen von 5, 11, 17, 23-Tetrasulfon-säurecalix [4] aren mit Paraquat wurde käufliches Paraquat der Firma Sig a genommen. Neben diesem gebräuchlichsten Trivialnamen wird es oft auch als Methyl iologen bezeichnet. Der systematische Name nach IUPAC lautet: 1, 1 '-Dimethyl-4, 4 '- bispyridinium-dichlorid (Formel IV) .In the investigation of the interactions of 5, 11, 17, 23-tetrasulfonic acid calix [4] arene with paraquat, commercial paraquat from the company Sig a was used. In addition to this most common trivial name, it is often referred to as a methyl iologist. The systematic name according to IUPAC is: 1, 1 '-dimethyl-4, 4' - bispyridinium dichloride (formula IV).
Paraquat ist ein sehr wirksames Kontaktherbizid und hat als solches seit vielen Jahrzehnten eine breite Anwendung gefunden. Die toxische Wirkung bei Pflanzen beruht auf einer Hemmung der Photosynthese durch Bildung radikalischer Zwischenstufen, die die NADP- Reduktion verhindern. Dadurch wird die Energieübertragung behindert . Es wird im Feld in Gegenwart von Licht und 'Sauerstoff rasch zu ungiftigen, gut waser- löslichen Verbindungen abgebaut, wodurch es ein gutes Mittel ist, die Unkrautbekämpfung zeitlich gezielt und relativ umweitschonend durchzuführen'. Durch Paraquat sind beim Menschen immer wieder zahlreiche akute und chronische Vergiftungen bei der landwirtschaftlichen Anwendung oder bei Suizidversuchen aufgetreten. Es treten dabei Symptome wie Augen- Schädigungen, Nieren- und Leberschäden, Gastritis sowie Lungenerkrankungen bis zum Tod durch Ersticken auf. Therapeutische Maßnahmen sind beschränkt, da es kein spezifisches Antidot gibt. Die Adsorption an Aktivkohle oder Kohlefiltern ist schwach, weshalb nach stärkeren Wechselwirkungen mit Adsorbentien gesucht wird. Paraquat is a very effective contact herbicide and as such has been widely used for many decades. The toxic effect on plants is based on the inhibition of photosynthesis by the formation of radical intermediates which prevent the NADP reduction. This hinders the transmission of energy. It is 'non-toxic to rapidly oxygen, reduced well waser- soluble compounds, whereby it is a good way to carry out the control of weeds in time selectively and relatively umweitschonend' in the field in the presence of light and. Paraquat has repeatedly resulted in numerous acute and chronic poisonings in humans when used in agriculture or when attempting suicide. Symptoms such as eye damage, kidney and liver damage, gastritis and lung diseases occur until death from suffocation. Therapeutic measures are limited because there is no specific antidote. Adsorption on activated carbon or carbon filters is weak, which is why stronger interactions with adsorbents are sought.
Claims
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003245917A AU2003245917A1 (en) | 2002-06-12 | 2003-06-06 | Filter material for toxins, bacteria, viruses, and other harmful physiological substances |
| EP03737999A EP1526910A2 (en) | 2002-06-12 | 2003-06-06 | Filter material for toxins, bacteria, viruses, and other harmful physiological substances |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10226099A DE10226099A1 (en) | 2002-06-12 | 2002-06-12 | Filter material for toxins, bacteria, viruses and other physiological pollutants |
| DE10226099.0 | 2002-06-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2003105990A2 true WO2003105990A2 (en) | 2003-12-24 |
| WO2003105990A3 WO2003105990A3 (en) | 2004-04-01 |
Family
ID=29718988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2003/005957 Ceased WO2003105990A2 (en) | 2002-06-12 | 2003-06-06 | Filter material for toxins, bacteria, viruses, and other harmful physiological substances |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1526910A2 (en) |
| AU (1) | AU2003245917A1 (en) |
| DE (1) | DE10226099A1 (en) |
| WO (1) | WO2003105990A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8556085B2 (en) | 2010-11-08 | 2013-10-15 | Stuart Bogle | Anti-viral device |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989008092A1 (en) * | 1988-02-29 | 1989-09-08 | The Flinders University Of South Australia | Removal of organic compounds from fluids |
| US5312837A (en) * | 1991-01-29 | 1994-05-17 | Genelabs Technologies, Inc. | Method of treating viral infections with aryl macrocyclic compounds |
| AU4803393A (en) * | 1992-08-06 | 1994-03-03 | Genelabs Technologies, Inc. | Inhibition and treatment of infection by enveloped virus with calix(n) arene compounds |
| AU1545395A (en) * | 1994-01-24 | 1995-08-08 | Stephen J. Harris | Calixarene-based compounds having antibacterial, antifungal, anticancer-hiv activity |
| EP0883432A1 (en) * | 1996-02-28 | 1998-12-16 | Transdiffusia S.A. | Process for the recovery of volatile low molecular compounds |
| JPH11209740A (en) * | 1998-01-19 | 1999-08-03 | Kurita Water Ind Ltd | Separating agent for halogenated ethylene compounds |
-
2002
- 2002-06-12 DE DE10226099A patent/DE10226099A1/en not_active Withdrawn
-
2003
- 2003-06-06 WO PCT/EP2003/005957 patent/WO2003105990A2/en not_active Ceased
- 2003-06-06 AU AU2003245917A patent/AU2003245917A1/en not_active Abandoned
- 2003-06-06 EP EP03737999A patent/EP1526910A2/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8556085B2 (en) | 2010-11-08 | 2013-10-15 | Stuart Bogle | Anti-viral device |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003245917A8 (en) | 2003-12-31 |
| DE10226099A1 (en) | 2004-01-08 |
| AU2003245917A1 (en) | 2003-12-31 |
| WO2003105990A3 (en) | 2004-04-01 |
| EP1526910A2 (en) | 2005-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0533727B1 (en) | ADSORBENT MATERIAL FOR SELECTIVE REMOVAL OF LDL OR/AND vLDL | |
| DE3115608C2 (en) | Device for the adsorption of blood proteins | |
| Hostettmann | Saponins with molluscicidal activity from Hedera helixL | |
| DE69605395T2 (en) | Device for the extracoporeal removal of toxins, in particular cytokines | |
| DE4331358A1 (en) | Process for the quantitative selective removal or preparation of tumor necrosis factor (TNF) and / or lipopolysaccharides (LPS) from aqueous liquids | |
| DE69834651T2 (en) | FILTER MATERIAL FOR THE REMOVAL OF WHITE BLOOD BODIES | |
| DE60009723T2 (en) | METHOD FOR SEPARATING LACTON-CONTAINING COMPOUNDS OF HIGH MOLECULAR WEIGHT | |
| DE10045434A1 (en) | Adsorbent with differently modified surface areas, process for its production and use thereof | |
| DE69837993T2 (en) | ADSORBENTS FOR TOXIC SHOCKSYNDROME TOXIN-1, METHOD FOR REMOVING TOXIN BY ADSORBTION | |
| DE69218477T2 (en) | Medical material, process for its manufacture and medical device | |
| EP0548794A2 (en) | Polyaspartamide derivative as adsorbent for bile acids, polyaspartamide loaded with bile acids and preparation and use as a drug | |
| DE69011985T2 (en) | Medical material, process for its manufacture and medical device in which this material is used. | |
| DE3926539C2 (en) | ||
| DE69330458T3 (en) | METHOD FOR OBTAINING A HIGH-PURITY FACTOR VIII / WILLEBRAND FACTOR COMPLEX THROUGH ANION EXCHANGE CHROMATOGRAPHY | |
| DE10011481A1 (en) | Adsorbent for lowering the concentration of fibrinogen and / or fibrin, use of the adsorbent for the production of an adsorber and adsorber with the adsorbent | |
| EP1526910A2 (en) | Filter material for toxins, bacteria, viruses, and other harmful physiological substances | |
| DE69219384T2 (en) | Packs of protein bound to carrier via spacers | |
| EP1104674A1 (en) | O,o'-dihydroxy azo dyes as medicinal components with TPO-agonistic or -synergetic activity | |
| DE3046565A1 (en) | METHOD FOR SEPARATING BLOOD SERUM PROTEINS | |
| EP1132129A1 (en) | Method for preparing an adsorbent to lower fibrinogen and/or fibrin concentration, adsorbent and use thereof for manufacturing an adsorber | |
| DE10147463A1 (en) | Process for purifying whole blood | |
| DE69525297T2 (en) | PROTEINS CONTAINING ADSORBENS FOR KETOAMINE | |
| DE3715447C2 (en) | Process for the preparation of a mixture of O- (beta-hydroxyethyl) diosmines | |
| CN106939031B (en) | A kind of spirosolane type glycoalkaloid and preparation method thereof and purposes | |
| DE102024102676A1 (en) | Process for the biosynthesis and purification of asperparaline A |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2003737999 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2003737999 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |